197 related articles for article (PubMed ID: 22354374)
1. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity.
Reyes-Sandoval A; Rollier CS; Milicic A; Bauza K; Cottingham MG; Tang CK; Dicks MD; Wang D; Longley RJ; Wyllie DH; Hill AV
Mol Ther; 2012 Aug; 20(8):1633-47. PubMed ID: 22354374
[TBL] [Abstract][Full Text] [Related]
2. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.
Anderson RJ; Hannan CM; Gilbert SC; Laidlaw SM; Sheu EG; Korten S; Sinden R; Butcher GA; Skinner MA; Hill AV
J Immunol; 2004 Mar; 172(5):3094-100. PubMed ID: 14978115
[TBL] [Abstract][Full Text] [Related]
3. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A
Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295
[TBL] [Abstract][Full Text] [Related]
5. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.
Gilbert SC; Schneider J; Hannan CM; Hu JT; Plebanski M; Sinden R; Hill AV
Vaccine; 2002 Jan; 20(7-8):1039-45. PubMed ID: 11803063
[TBL] [Abstract][Full Text] [Related]
6. CD8+ T effector memory cells protect against liver-stage malaria.
Reyes-Sandoval A; Wyllie DH; Bauza K; Milicic A; Forbes EK; Rollier CS; Hill AV
J Immunol; 2011 Aug; 187(3):1347-57. PubMed ID: 21715686
[TBL] [Abstract][Full Text] [Related]
7. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
8. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
9. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
Dégano P; Schneider J; Hannan CM; Gilbert SC; Hill AV
Vaccine; 1999 Nov; 18(7-8):623-32. PubMed ID: 10547421
[TBL] [Abstract][Full Text] [Related]
10. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
Lambe T; Carey JB; Li Y; Spencer AJ; van Laarhoven A; Mullarkey CE; Vrdoljak A; Moore AC; Gilbert SC
Sci Rep; 2013; 3():1443. PubMed ID: 23485942
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
Schneider J; Gilbert SC; Blanchard TJ; Hanke T; Robson KJ; Hannan CM; Becker M; Sinden R; Smith GL; Hill AV
Nat Med; 1998 Apr; 4(4):397-402. PubMed ID: 9546783
[TBL] [Abstract][Full Text] [Related]
12. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
[TBL] [Abstract][Full Text] [Related]
13. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
[TBL] [Abstract][Full Text] [Related]
14. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
Betts G; Poyntz H; Stylianou E; Reyes-Sandoval A; Cottingham M; Hill A; McShane H
PLoS One; 2012; 7(12):e50447. PubMed ID: 23284637
[TBL] [Abstract][Full Text] [Related]
15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
Reyes-Sandoval A; Berthoud T; Alder N; Siani L; Gilbert SC; Nicosia A; Colloca S; Cortese R; Hill AV
Infect Immun; 2010 Jan; 78(1):145-53. PubMed ID: 19858306
[TBL] [Abstract][Full Text] [Related]
17. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
18. Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.
Pillai VK; Kannanganat S; Penaloza-Macmaster P; Chennareddi L; Robinson HL; Blackwell J; Amara RR
Vaccine; 2011 Jul; 29(33):5399-406. PubMed ID: 21651938
[TBL] [Abstract][Full Text] [Related]
19. Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.
Forbes EK; Biswas S; Collins KA; Gilbert SC; Hill AV; Draper SJ
J Immunol; 2011 Oct; 187(7):3738-50. PubMed ID: 21876036
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
